Please assess the completion status of the following clinical trial:

Trial Title: Targeting Abdominal Perfusion Pressure in Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (age ≥ 18)~2. Septic shock - identified as early as possible as evidenced by:~   1. Clinical diagnosis of sepsis defined as documented or suspected infection with the use of antibiotic administration OR~  2. Meets qSOFA (Quick Sequential Organ Failure Assessment) Criteria per the Sepsis-3 definitions:~   i. Respiratory rate ≥ 22/min ii. Altered mentation iii. Systolic blood pressure ≤ 100 mmHg AND c. Shock dependent on vasopressor therapy following initial 12-hour Resuscitation Period refractory to further volume expansion as assessed by clinical treatment team; this may be supported by either: i. Lack of blood pressure response following fluid bolus or passive leg raise ii. Hemodynamic data as available (e.g. PPV \[positive pressure ventilation\], SVV \[stroke volume variation\], echo, PAOP \[pulmonary artery occlusion pressure\], right-heart catheterization, etc.)~3. Indication for a urinary bladder catheter (or one currently in place)~4. Indication for an arterial line (or one currently in place at any site)~FOR MONITORING PHASE OF STUDY (MONITORING GROUP)~1. All of the above criteria for the Resuscitation and Observational Periods of the study~2. Intra-abdominal pressure \< 8 mmHg~FOR INTERVENTION PHASE OF STUDY (APP VS MAP GROUPS)~1. All of the above criteria for the Resuscitation and Observational Periods of the study~2. Intra-abdominal pressure ≥ 8 mmHg~Exclusion Criteria:~1. Inability to receive a urinary bladder catheter~2. Chronic suprapubic catheter in place~3. Cirrhosis/end stage liver disease, including Child-Pugh class C~4. Severe AKI \[acute kidney injury\] as defined by life-threatening electrolyte, acidemia, or other indication for imminent emergent dialysis needs within 12 hours of hospital admission~5. Evidence of chronic renal failure stage 5 (including serum creatinine values consistent with CKD 5 \[chronic kidney disease, stage 5\] or dialysis dependence) in 12-months prior to enrollment~6. Active gastrointestinal bleed likely causing/contributing to the hemodynamic instability~7. Acute intra-abdominal trauma (including intraabdominal surgery within the prior 30 days)~8. Acute pancreatitis with no established source of infection~9. Treating physician deems aggressive care is unsuitable, or has decided to de-escalate care \[Do Not Resuscitate (DNR) patients receiving standard care are still eligible\]~10. In the opinion of the treating attending physician the patient is unsuitable for the study for any legitimate reason including lack of equipoise, anticipated imminent significant deterioration, anticipated imminent recovery, incarceration, pre-existing medical or psychiatric condition that treating attending physician deems not appropriate for study, or interfering medications~11. Known previous or concurrent enrollment in a treatment clinical trial that, in the opinion of the investigator, might interfere with the objectives/endpoints of this clinical trial~12. Known contraindication to bladder pressure measurement~13. Known pregnancy~14. Suspected or known increased intracranial pressure requiring active neurosurgical consultation~15. Cardiogenic shock requiring extracorporeal support~16. Any requirement for chest compressions prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monitoring Group (Type: NO_INTERVENTION): Patients that sustain intra-abdominal pressure of \< 8 mmHg for 48 hours from sepsis diagnosis. Patients will be monitored and given sepsis standard of care.
- Mean Arterial Pressure (MAP) Group (Type: ACTIVE_COMPARATOR): Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
- Abdominal Perfusion Pressure (APP) Group (Type: EXPERIMENTAL): Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).